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 Chapter 2 
 In Vivo Microdialysis to Study Striatal Dopaminergic 
Neurodegeneration 
 Giuseppe  Di Giovanni ,  Massimo  Pierucci ,  Mauro  Pessia , 
and  Vincenzo  Di Matteo  
 Abstract 
 Microdialysis cerebral technique has been widely employed in order to study neurotransmitter release. This 
technique presents numerous advantages such as it allows work with sample in vivo from freely moving 
animals. Different drugs in different points implanted probes in several brain areas can be infused simulta-
neously by means of microdialysis. Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
that is primarily characterized by the degeneration of dopamine (DA) neurons in the nigrostriatal system, 
which in turn produces profound neurochemical changes within the basal ganglia, representing the neural 
substrate for Parkinsonian motor symptoms. Over the years, a broad variety of experimental models of the 
disease have been developed and applied in diverse animal species. The two most common toxin models 
used employ 6-hydroxydopamine (6-OHDA) and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/1-
methyl-4-phenilpyridinium ion (MPTP/MPP + ), either given systemically or locally applied into the nigros-
triatal pathway, to resemble PD features in animals. Both neurotoxins selectively and rapidly destroy 
catecholaminergic neurons, although with different mechanisms. Since in vivo microdialysis coupled to 
high-performance liquid chromatography (HPLC) is an established technique for studying physiological, 
pharmacological, and pathological changes of a wide range of low molecular weight substances in the brain 
extracellular  fl uid, here we describe a rapid and simple microdialysis technique that allows the direct quan-
titative study of the damage produced by 6-OHDA and MPP + toxins on dopaminergic (DAergic) striatal 
terminals of rat brain. 
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 Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
that is primarily characterized by the degeneration of dopamine 
(DA) neurons in the nigrostriatal system, which in turn produces 
profound neurochemical changes within the basal ganglia 
(Fig.  1 ), representing the neural substrate for Parkinsonian motor 
 1.  Introduction
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symptoms  ( 1 ) . The pathogenesis of the disease is still not completely 
understood, but environmental and genetic factors are thought to 
play relevant roles. Important factors include formation of free 
radicals, impaired mitochondrial activity, increased sensitivity to 
apoptosis, excitoxicity, and in fl ammation  ( 1,  2 ) . It appears clear 
that understanding the etiopathogenesis of PD, the modalities 
 Fig. 1.  Simpli fi ed diagram illustrating the changes occurring in the basal ganglia functional 
organization in Parkinson’s disease, with respect to normal condition. Relative thickness 
of  arrows indicate the degrees of activation of the transmitter pathways. The basal ganglia 
participate in larger circuits that also include cortex and thalamus. The striatum is the 
principal input structure of the basal ganglia, and the internal segment of the globus pal-
lidus (GPi) and the substantia nigra pars reticulata (SNr) are the major output structures, 
projecting toward the thalamus and brainstem. According to conventional anatomical 
models, basal ganglia input and output structures are linked via a monosynaptic “direct” 
pathway and a polysynaptic “indirect” pathway that involves the external pallidal segment 
(GPe) and the subthalamic nucleus (STN). Dopamine released from terminals of the 
nigrostriatal (SNc) projection is thought to modulate basal ganglia activity by inhibiting 
activity along the “indirect” pathway through stimulation of dopamine D2 receptors and 
enhancing activity along the “direct” pathway by the stimulation of the dopamine D1 
receptor. The same model has been applied to explain aspects of the pathophysiology of 
parkinsonism. Loss of striatal dopamine is believed to result in increased striatal inhibition 
of GPe, leading to disinhibition of STN neurons and to increased basal ganglia output from 
GPi and SNr. Increased and altered basal ganglia output to the thalamus is thought to 
disturb cortical processing, which is ultimately responsible for the development of many 
of the Parkinsonian motor signs. Dopamine (DA)  un fi lled arrows , glutamate (GLU)  black 
arrows ,  g -aminobutyric acid (GABA)  gray arrows. 
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whereby the neurodegenerative process begins and progresses, is 
fundamental for the development of drugs to slow or prevent the 
progression of PD. Most of the progress in this  fi eld has been 
gained thanks to the toxin models of PD. Over the years, a broad 
variety of experimental models of the disease have been developed 
and applied in diverse animal species. The two most common toxin 
models used employ the 6-hydroxydopamine (6-OHDA) and the 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/1-methyl-4-
phenilpyridinium ion (MPTP/MPP + ), given either systemically or 
locally applied into the nigrostriatal pathway, to resemble PD fea-
tures in animals. Both neurotoxins selectively and rapidly destroy 
catecolaminergic neurons, though with different mechanisms  ( 3, 
 4 ) . In this regard, in vivo microdialysis, a well-established method 
for monitoring the extracellular levels of neurotransmitters in the 
CNS  ( 5 ) allows online estimates of neurotransmitters in living 
animals and is a suitable method for monitoring the extracellular 
levels of neurotransmitters during local administration of pharma-
cological agents. Different doses of a drug or a combination of 
agonists and antagonists can be administered in the same experi-
ment without adding any  fl uid to extracellular spaces  ( 6 ) . Therefore, 
researchers have extensively used this method as a tool for the study 
of pathophysiologic changes in chemical processes of Parkinsonian 
brain, and particularly, the infusion of drugs (toxins) through the 
microdialysis cannula (Fig.  2 ) ( retrodialysis ), has permitted the 
development of some interesting animal models of PD as well as 
contemporary study of the effects of unilateral lesions of nigrostri-
atal dopamine neurons  ( 7 ) . Here we will describe a rapid and sim-
ple microdialysis technique that allows the direct quantitative study 
of the damage produced by 6-OHDA and/or MPP + toxins on 
DAergic striatal terminals of rat brain. 
 This rapid sampling procedure is completed in 2 days: in the 
 fi rst day of the experiment a  fi xed toxin (e.g., MPP + or 6-OHDA) 
dissolved in Ringer solution is perfused through the microdialysis 
probe, in a target area of the striatum for a short time (10–15 min) 
with a  fi xed concentration (generally 1–10 mM, or more, depend-
ing from the used substance), to induce neurodegeneration of the 
nigrostriatal system. Forty-eight hours after (day 2), the amount of 
DA released by the perfusion (challenge) of a second dose of MPP + 
could be indicative of the damage produced by a previous perfu-
sion of a toxic compound, since it could be proportional to the 
number of remaining DAergic terminals (Fig.  3 ) and the decreases 
in DA over fl ow re fl ecting DA nerve terminal degeneration  ( 8 ) . 
Indeed, the massive DA extracellular output after the  fi rst MPP + or 
6-OHDA perfusion is an index of DAergic cell disruption  ( 9,  10 ) . 
Thus, this method is suitable to study different drug-induced 
DAergic toxicity in the nigrostriatal system and also to estimate the 
quantitative damage induced by these toxins. 
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 As already mentioned, microdialysis is a technique designed to 
monitor the chemistry of extracellular spaces in living tissue and 
allows monitoring of neurotransmitters released from practically 
any region of the brain. It consists of the  fi ltration of water-soluble 
substances in extracellular  fl uid through a dialysis membrane 
(Fig.  2 ) into a perfusion  fl uid that is collected and then analyzed for 
the substances of interest. With this technique, extracellular neu-
rotransmitter levels and other molecules equilibrate with the solu-
tion  fl owing through a dialysis probe implanted in discrete brain 
areas. Usually microdialysis is coupled with high performance liq-
uid chromatography (HPLC), making it possible to detect extra-
cellular levels of many compounds, from small neurotransmitters to 
larger peptides  ( 5,  6 ) . The core of microdialysis is the dialysis probe 
(Fig.  2 ) designed to mimic a blood capillary. When a physiological 
salt solution (arti fi cial cerebral  fl uid solution, aCSF) is slowly 
pumped through the microdialysis probe, the solution equilibrates 
with the surrounding extracellular tissue  fl uid. After a while, it will 
then contain a representative proportion of the tissue  fl uid’s mol-
ecules, and the microdialysate is extracted and later analyzed in the 
laboratory, usually by HPLC. The body of any “freely moving” 
awake microdialysis system consists of a dual-channel microdialysis 
 1.1.  Brief Description 
of Microdialysis 
Process
 Fig. 2.  The Microdialysis probe: A microdialysis (MD) probe is usually constructed as a concentric tube where the perfusion 
 fl uid enters through an inner tube,  fl ows to its distal end, exits the tube, and enters the space between the inner tube and 
the outer dialysis membrane. The direction of  fl ow is now reversed and the  fl uid moves toward the proximal end of the 
probe. This is where the “dialysis” takes place, i.e., the diffusion of molecules between the extracellular  fl uid (ECF) and the 
perfusion  fl uid. Vice versa, by reverse dialysis is possible the introduction of a substance into the extracellular space via 
the microdialysis probe. The inclusion of a higher amount of a drug in the perfusate allows the drug to diffuse through the 
microdialysis membrane to the tissue. This technique not only allows the local administration of a substance but also 
permits the simultaneous sampling of the extracellular levels of endogenous compounds. 
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swivel that has a quartz-lined center and side channels to minimize 
dead volume and prevent neurotransmitter oxidation (Fig.  4 ). 
Dialysate is typically infused through one channel of the swivel, 
removed through the other, and then collected with a fraction 
collector or into a microvial. The head block tether and lever arm 
are necessary to minimize stress on microdialysis probes. The coun-
terbalanced lever arms generally move vertically and horizontally 
with the animal to prevent slack in the tether. Most of the lever 
arms use a mass as the counterbalance, the animal can generally stay 
in a round polycarbonate container that prevents it from damaging 
the probes (Fig.  4 ). 
 A microdialysis probe is usually constructed as a concentric tube 
(Fig.  2 ). The perfusion  fl uid, delivered by a syringe microdialysis 
pump (Fig.  4 ) at low  fl ow rate (perfusion rates of 0.3–3  m l/min are 
typically used depending upon the volume, sample collection time, 
and analytical sensitivity needed, with typical sample collection 
times ranging from 1 to 20 min). It enters through an inner tube, 
 Fig. 3.  The 2-day test-challenge microdialysis method. Time course of the effect of 15 min 1 mM MPP + perfusion 24 h later 
after perfusion of 6-OHDA (1 mM for 15 min) ( a ), and 1 mM-15 min MPP + ( c ) on extracellular dopamine output in the corpus 
striatum. Each data point represents mean ± SEM of absolute levels of DA, without considering probe recovery. Statistical 
analysis shows that MPP + and 6-OHDA perfused in the  fi rst day of the experiment induced neurodegeneration of nigrostri-
atal pathway as shown by the decrease in DA release after MPP + challenge in the second day (one-way ANOVA, followed 
by Fisher’s PLSD  post hoc test: * p < 0.05; ** p < 0.01 6-OHDA vs. Ringer (Control group), and ** p < 0.01 MPP + vs. Ringer). 
In ( b )–( d ) histograms represent the total DA output measured as the sum of  fi ve (100 min) consecutive samples after the 
same conditions of ( a ) and ( c ) (** p < 0.01 6-OHDA ( b ) and MPP + ( d ) vs. Ringer). Modi fi ed from  ( 13 ). 
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 fl ows to its distal end, exits the tube, and enters the space between 
the inner tube and the outer dialysis membrane, which may be of 
different lengths, depending on the brain region analyzed. The 
dialysis membrane is semipermeable and permits free transport of 
some but not all solutes. Permeability is typically limited to com-
pounds with molecular masses <20,000 Da. The direction of  fl ow is 
now reversed and the  fl uid moves toward the near end of the probe 
(see Fig.  2 ). Dialysis (the diffusion of molecules between the extra-
cellular and perfusion  fl uids) takes place at the end of the probe, in 
the membrane space. It is important to realize that dialysis is an 
exchange of molecules in both directions. The difference in con-
centration through the membrane governs the direction of the gra-
dient. It is possible to collect an endogenous compound at the same 
time that an exogenous compound such as a drug is introduced 
into the tissue. The gradient of a particular compound into the 
membrane depends on the difference in concentration between the 
perfusate and the extracellular  fl uid and also on the  fl ow velocity 
inside the microdialysis probe. The absolute recovery (mol/time 
unit) of a substance from the tissue or of substances entering the 
tissue from the probe depends on (1) the  fl ow rate of the perfusion 
 fl uid, (2) the length of the membrane, (3) the “cut-off” of the 
dialysis membrane, and (4) the diffusion coef fi cient of the com-
pound through the extracellular  fl uid, all important factors to con-
sider for a microdialysis experiment. The advantages and limitations 
of microdialysis techniques have been reviewed in detail  ( 5,  6,  11 ) . 
Moreover, this is an ideal technique because multiple sampling of 
the brain and several regions in a living free-moving animal is pos-
sible. No clean-up procedures such as extraction and homogeniza-
tion of tissue are required before analysis. Behavioral and 
pharmacology studies can be contemporaneously performed. 
Neurochemistry around the brain probes can be continuously 
monitored. Various drugs can be locally administered in the speci fi c 
brain areas, without having to inject additional volumes. 
 Fig. 4.  Photograph of “in vivo freely moving” microdialysis setup. It is formed by a dual-channel 
microdialysis swivel, head block tether, and lever arm. The aCSF is delivered into the 
microdialysis probe by a microinjection syringe pump. 
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 Male Sprague–Dawley rats (weighing 340–380 g) are obtained 
from Charles River, Calco, Italy. 
 Anesthetic: Chloral hydrate. 
 Stereotaxic atlas for rat  ( 12 ) . 
 Stereotaxic frame (David Kopf Instruments, Tujunga, USA) (Fig.  5 ). 
 Microdialysis guide cannula for CMA/12 probe (Carnegie 
Medicin, Stockholm, Sweden) (Fig.  4 ). 
 Microdialysis probe (CMA/12, 3 mm length, 500  m m outer diam-
eter, Carnegie Medicin, Stockholm, Sweden) (Fig.  4 ). 
 Scalpel. 
 Spatula. 
 Dental or hand drill. 
 Jeweler’s forceps and screwdriver. 
 3/16 in. bone stainless steel screws. 
 Methylacrylic cement. 
 Fluorinated ethylene propylene (FEP) tubing 0.12 mm inner 
diameter (Carnegie Medicin, Stockholm, Sweden). 
 Tubing Adaptors (for connecting FEP Tubing to the probe, swivel, 
liquid switch, and syringes; Carnegie Medicin, Stockholm, 
Sweden). 
 2.  Materials
 2.1.  For Microdialysis
 Fig. 5.  A typical stereotaxic apparatus: The animal is positioned on the heat-controlled 
blanket (1), the left (2), and right (2 ¢ ) ear bars and the incisor adaptor with the nose clamp 
(3) are used to  fi x the animal’s head, and the probe holder (4) is controlled in the  x ,  y , and 
 z planes by the stereotaxic arm. 
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 CMA 110 Liquid Switch (Carnegie Medicin, Stockholm, Sweden) 
(Fig.  4 ). 
 Two-channel liquid swivel (Carnegie Medicin, Stockholm, Sweden) 
(Fig.  4 ). 
 CMA/120 system for freely moving animals (Carnegie Medicin, 
Stockholm, Sweden) (Fig.  4 ). 
 Glass Luer-Lock gas-tight microsyringes (Hamilton). 
 Microperfusion pump (Harvard Apparatus syringe infusion pump 
22, USA) (Fig.  4 ). 
 Collection plastic vials (e.g., 0.2-ml microcentrifuge tubes) (Fig.  4 ). 
 Na 2 HPO 4 . 
 NaH 2 PO 4 . 
 MgCl 2 . 
 CaCl 2 . 
 KCl. 
 NaCl. 
 H 2 O. 
 GS (0.22  m m) Millipore glass  fi lters. 
 1-Methyl-4-phenylpiridinium iodide (MPP + ) from Sigma-Aldrich, 
St. Louis, MO, USA. 
 6-Hydroxydopamine hydrobromide (6-OHDA) from Aldrich 
Chem. Co. Milwakee. WI, USA. 
 HPLC with electrochemical detection (HPLC/EC) system con-
sisting of
 HPLC dual-piston pump (LC-10 ADvp pump, Shimadzu Italia, 
Milano) equipped with pulse dampener. 
 Manual injector (20- m l sample loop/gas-tight HPLC glass 
microsyringe). 
 Coulochem detector (Coulochem II, ESA, Bedford, MA, USA) 
equipped with a dual electrode analytic cell (model 5014; ESA, 
Bedford, MA, USA). 
 Computer software program. 
 Hypersil column (C18, 4.6 × 150 mm, 5  m m, Sigma-Aldrich 
Chemicals, USA). 
 10  m M Monoamine standard working solutions (in 0.1 N percloric 
acid and 0.05% Na 2 S 2 O 5 ) and dilutions (in aCSF) bracketing 
those estimated for the samples: 
 4-Hydroxybenzoic acid (4-HBA). 
 3,4 Dihydroxybenzoic acid (3,4-DHBA). 
 Dopamine hydrochloride (DA). 
 2.2.  Arti fi cial 
Cerebrospinal Fluid
 2.3.  Drugs
 2.4.  For HPLC Analysis
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 Dihydroxyphenilacetic acid (DOPAC). 
 HPLC-grade water. 
 Filtration apparatus consisting of 
 Borosilicate glass vacuum  fl ask. 
 Fritted  fi lter support and spring clamp. 
 0.22- m m Filter discs (e.g., Millipore). 
 Vacuum source. 
 Ultrapure helium with regulator and Te fl on tubing. 
 The mobile phase is composed of 70 mM NaH 2 PO 4 , 0.1 mM 
Na 2 EDTA, 0.7 mM triethylamine, 0.1 mM octylsulfonic acid, and 
10% methanol, adjusted to pH 4.8 with orthophosphoric acid. 
 Ascorbate. 
 4% Paraformaldehyde. 
 1 M Phosphate buffer, pH 7.4 (PBS). 
 Sucrose in PBS, 
 Isopentane −45°C. 
 Cryostat microtome, 
 Gelatine-coated slices. 
 0.6% Hydrogen peroxide. 
 Methanol. 
 Goat serum. 
 Humid chamber. 
 Policlonal rabbit anti- b TH (Abcam Limited Cambridge, UK) 
0.15  m g/ m l diluted 1:200 in PBS Triton-X-100. 
 Biotinylated goat anti-rabbit IgG (Vector, 1:200). 
 Avidin Biotinylated horseradish peroxidase macromolecular 
Complex solution (Vectastain ® ABC system, Vector Labs, Inc., 
Burlingame, CA). 
 Standard (Vector) diaminobenzidine/hydrogen peroxidase chro-
mogen (peroxidase substrate kit DAB; Vector Labs, Inc., 
Burlingame, CA). 
 
 For short- or long-term measurements of neurochemicals in the con-
scious animal, a guide cannula is typically implanted above the region 
of interest. This provides support and protection of the more delicate 
dialysis probe and is a means to introduce the probe without the 
trauma of a just-completed surgery. Due to trauma resulting from 
 2.5.  Tyrosine 
Hydroxylase Immuno
histochemistry
 3.  Methods
 3.1.  Surgery for 
Microdialysis
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the introduction of the probe or the probe/cannula assembly into 
the tissue, the probe is left in situ for some hours prior to the start of 
experiments. During this period, the probe is perfused with physio-
logical aCSF. 
 Male Sprague–Dawley rats (Charles River, Calco, Italy) weigh-
ing 340–380 g are used. The animals are kept at constant room 
temperature (21 ± 1°C) and relative humidity (60 ± 5%) under a 
regular light/dark schedule (light 8.00–20.00 h). Food and water 
are freely available. Procedures involving animals and their care are 
conducted in conformity with the institutional guidelines that are 
in compliance with national (D.L. n. 116, G.U., suppl. 40, 18 
Febbraio 1992) and international laws and policies ( EEC Council 
Directive 86/609, OJ L 358,1, Dec. 12, 1987;  NIH Guide for the 
Care and Use of Laboratory Animals , NIH Publication N. 85-23, 
1985 and Guidelines for the Use of Animals in Biomedical Research, 
Thromb. Haemost. 58, 1078-1084, 1987).
  1.  Prior to surgery, all surgical instruments are autoclaved or ster-
ilized chemically before the probe implantation, a check is 
made for leaks and air bubbles. A  fi nal check is made to ensure 
that the active length of the probe extends the appropriate dis-
tance from the guide cannula tip. 
  2.  The rat is gently restrained and injected intraperitoneally (i.p.) 
with chloral hydrate (400 mg/kg, i.p.). Other anesthetics can 
be used. 
  3.  The animal is mounted in the ear bars of the stereotaxic apparatus 
(Fig.  5 ). If the animal is correctly positioned, only movement in 
the dorsoventral plane should be possible (see Note 1). 
  4.  A midline incision is made using the scalpel blade to pierce the 
skin. 
  5.  Fascia and connective tissue are scraped away. The entire area 
is dried with a cotton sponge or Q-tips (see Note 2). The 
bregma is identi fi ed (intersection of the coronal suture with 
midline) and used to determine the vertical zero coordinate. 
  6.  The guide cannula is attached into the stereotaxic holder and 
straighten (Fig.  5 ). 
  7.  The cannula is lowered so that it is centered on the bregma. 
The anteroposterior (AP) and lateral (L) coordinates are read 
from the scale and added or subtracted from the stereotaxic 
coordinates of striatum. 
  8.  By using a 3-Dimensional map of the brain (stereotaxic atlas) 
along with vernier scales on the apparatus, the guide cannula is 
placed over the left corpus striatum (AP = 0.8, L = 3.0, V = −3.0 
from the dura surface and respect to the bregma), according to 
the atlas of Paxinos and Watson 1986  ( 12 ) (see Note 3). 
  9.  Dental or hand drill with a burr sized is appropriately placed 
for the diameter of the guide cannula or probe assembly on an 
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electrode carrier or manipulator that has been modi fi ed to 
accommodate the width of drill. AP and L coordinates may be 
adjusted. Drill until the dura is punctured, using an up-and-down 
motion (see Note 4). 
  10.  Three additional holes are drilled around the cannula/probe 
hole; drill screw holes may be done far enough so as not to 
interfere with cannula insertion. Using jeweler’s forceps and a 
screwdriver, 3/16-in. bone screws are inserted into the holes 
(see Note 5). 
  11.  The cannula is slowly lowered into the target striatal region until 
the cannula’s base just rests on the dura surface. The ventral (V) 
coordinate is readed and the cannula lowered to −3.0 from the 
dura surface. Then, the skull is permanently  fi xed to with stain-
less steel screws and methylacrylic cement. 
  12.  The cement is allowed to dry and the holder is carefully 
removed. The cannula is secured in place by applying addi-
tional dental acrylic cement. 
  13.  aCSF is prepared: 147 mM Na + , 2.7 mM K + , 1 mM Mg 2+ , 
1.2 mM Ca 2+ , 154.1 mM Cl − , adjusted to pH 7.4 with 2 mM 
sodium phosphate buffer. The Ringer solution must be  fi ltered 
through type GS (0.22  m m) Millipore glass  fi lters before use 
(see Note 6). 
  14.  The microsyringe pump is prepared,  fi lled with aCSF, and 
attached to the pump. 
  15.  Probe is prepared (see Note 7), and connected to the swivel 
and syringe by FEP tubing and tubing adaptors (Fig.  4 ). 
  16.  The dummy cannula is removed from rat guide cannula and 
the probe is slowly inserted into the striatum (see Note 8). 
  17.  After the probe is inserted, the tether is attached to the animal 
and placed in the testing cage CMA/120 system for freely 
moving animals (see Note 9). Balance arm and liquid swivel are 
connected via a wire guide and spring clamp to a collar that is 
inserted over the neck of the rat, prior to insertion of the probe. 
Probe in fl ow and out fl ow tubing are secured to the wire guide, 
which pulls the liquid swivel/balance arm (Fig.  4 ). 
  18.  Following probe implantation, the rat is allowed to recovery 
from the surgery and the tissue from the physical damage ren-
dered by probe implantation. The probe is  fl ushed at 0.3  m l/
min overnight with aCSF. 
 The experiments are performed 24 h (day 1) after probe implanta-
tion, in awake, freely moving animals.
  1.  The corpus striatum is perfused at a  fl ow rate of 1  m l/min, and 
every 20 min samples of perfusate are collected in plastic vials 
and immediately assayed by HPLC with electrochemical detec-
tion (see below Sect.  3.5 ) (Fig.  7 ). 
 3.2.  First Day of 
Microdialysis: Lesion 
of Nigrostriatal DA 
System
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  2.  After establishing a steady baseline level in three consecutive 
samples (control value), MPP + iodide or 6-OHDA (1 mM) (see 
Note 10), dissolved in aCSF, is perfused for 10 min through the 
microdialysis probe in the rat striatum to induce neurodegenera-
tion of the nigrostriatal DAergic system, and then with the normal 
aCSF for further 2 h at a  fl ow rate of 1  m l/min (see Note 11). 
  3.  Afterwards the probe is  fl ushed at 0.3  m l/min until the next 
day of the experiment. 
 It is important to note that any pharmacological treatment to 
prevent neurodegeneration can be done 1 h before neurotoxins 
(prevention studies). Moreover, drugs can be systemically given 
after the  fi rst day of the experiment, to study its possible post-
lesion therapeutic effects. In this case the evaluation of neuronal 
integrity experiment (day 2 step) must be done at least after a week 
(see Note 12). 
 On the  fi rst day of the experiment it is important to verify that 
the drug treatment does not cause any signi fi cant effect on basal 
DA release in the rat striata, and does not modify the extracellular 
DA release induced by the neurotoxins, which indicate that it does 
not affect the DA-uptake mechanism or DA metabolism  ( 13,  14 ) . 
 To check the integrity of the DA system, after establishing a steady 
baseline level in three consecutive samples (control value), 1 mM 
MPP + (1 ml/min) is perfused for 10 min 1 day after (day 2) the  fi rst 
infusion of MPP + or 6-OHDA. Then the perfusion  fl uid is switched 
to normal aCSF for 2 h, until the end of experiment. The challenge 
with MPP + produces a maximal DA extracellular output 40 min 
after its infusion (Fig.  3 ). In a  fi rst experimental group, MPP + perfu-
sion produced a maximal DA increase of 819 ± 136 nmol in the non-
lesioned rats (aCSF), 260 ± 66 in the MPP + lesioned rats (Fig.  3c, d ). 
In a second group, MPP + perfusion produced a maximal DA increase 
of 805 ± 42 nmol in the non-lesioned (aCSF), 139 ± 22 in the 
6-OHDA lesioned rats (Fig.  3a, b ). The limited rise of DA follow-
ing the MPP + reperfusion is due to toxins-induced neuronal loss in 
the lesioned groups. The total amounts of DA, released in 100 min, 
were reduced in MPP + - or 6-OHDA-lesioned rats, challenged with 
MPP + on day 2, as compared to controls ( p < 0.01 vs. controls at 
Fisher’s PLSD test, in both groups) (Fig.  3 )  ( 13 ) . 
 Oxidative stress is de fi ned as an imbalance between the produc-
tion of reactive oxygen species (ROS) and a biological system’s 
ability to readily detoxify the reactive intermediates and/or easily 
repair the resulting damage. Increasing evidence suggests that 
reactive oxygen species are involved in the pathophysiology of PD. 
The microdialysis technique is suitable for measuring radical for-
mation in the extracellular space in vivo. After probe implantation 
and obtaining a stable baseline, the probe can be used to simulta-
neously deliver the stimulating agent (e.g., 6-OHDA or MPP + ) 
 3.3.  Second Day 
of Microdialysis
 3.4.  Microdialysis to 
Study Oxidative Stress
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and the trapping agent (see below) for the radical determination, 
without any puri fi cation steps before HPLC analysis. In addition, 
the implanted microdialysis probe allows reliable recording for 
many hours, and the animal serves as its own control. Due to the 
high reactivity and short half-life of ROS in biological tissue, indi-
rect methods for in vivo detection have been widely used. The 
method for in vivo measurement of the hydroxyl radicals (  .  OH) is 
based on the ability of the   .  OH to attack the benzene rings of aro-
matic molecules (Fig.  6 ). The salicylate (2-HBA) trapping tech-
nique is the most widely used technique for ROS detection in vivo 
and has previously been employed in experimental animal models 
of PD with microdialysis and HPLC coupled with an electro-
chemical detector (ECD)  ( 15– 17 ) . However, when ROS react 
with salicylate two adducts: 2,3- and 2,5-DHBA are formed 
(Fig.  6 ). Concerns have been raised with regard to the speci fi city 
of the salicylate trapping technique since enzymatic formation of 
2,5-DHBA occurs at extracerebral sites by the cytochrome p450 
system in the liver after systemic administration. In addition, 2,3-
DHBA is metabolized in the rat intestine, making it an unspeci fi c 
marker  ( 18– 20 ) . Salicylate may also chelate divalent metal ions 
 ( 21 ) , thus affecting hydroxyl radical formation. Finally, salicylate 
has been shown to affect the inducible nitric oxide synthase (iNOS) 
 ( 22 ) . Therefore, when a trapping method for ROS detection is 
employed a very careful evaluation of possible sources of sponta-
neous ROS formation may be made and these sources may be 
eliminated as far as possible. Plausible factors affecting hydroxylation 
 Fig. 6.  Reaction scheme of salicylate (2-HBA) with the hydroxyl radicals (  •  OH) to form 2,3- and 2,5-dihydroxybenzoate (2,3- 
and 2,5-DHBA) and 4-hydroxybenzoic acid (4-HBA) hydroxylation that forms the 3,4-dihydroxybenzoic acid (3,4-DHBA). 
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of DHBAs using microdialysis technique include time, use of 
metal ions, and reuse of microdialysis probes. The liquid switch 
perfusion with an arti fi cial physiological solution may possibly 
corrode some metal surfaces. Reusing the microdialysis probe 
resulted in increased DHBA production  ( 23 ) . Therefore, to reduce 
artifactual exogenous hydroxyl free radical production, all stainless 
steel may be eliminated from the microdialysis setup and HPLC 
system, the perfusing solutions may kept cold, shielded from the 
light and freshly prepared just before use. A sensitive and speci fi c 
hydroxybenzoate (4-hydroxybenzoic acid; 4-HBA) hydroxylation 
assay is also used in conjunction with HPLC–ECD to monitor 
hydroxyl radicals (  .  OH) production  ( 21,  23 ) . 4-HBA is known to 
trap hydroxyl radicals with equal ef fi cacy as salicylate  ( 21 ) . It offers 
a number of advantages compared to the use of salycilate:  fi rstly, 
only one isomer is formed by hydroxylation of 4-HBA, the 3,4-
DHBA (Fig.  7 ), therefore the signal due to   .  OH attack is not split 
between two compounds (2,3- and 2,5-DHBA), decreasing the 
sensitivity of the assay, as in the case of salycilate (Fig.  7 ). Secondly, 
the systemic production of 3,4-DHBA following administration 
of a large bolus of 4-HBA in vivo is negligible compared to the 
in vivo enzymatic hydroxylation of salycilate. Lastly, salicylate is an 
effective chelator of divalent metal ions, including Fe 2+ . As Fe 2+ 
catalyzes the decomposition of H 2 O 2 to OH, this may result in an 
over estimation of apparent   .  OH production due to its increased 
local formation  ( 21,  23 ) . On the other hand, the formation of 
3,4-DHBA may re fl ect either the production of hydroxyl radicals 
or other highly reactive species such as peroxynitrite produced by 
the reaction between superoxide anions and nitric oxide  ( 24 ) . 
Thus, the formation of 3,4-DHBA is likely to re fl ect ROS produc-
tion but is not speci fi c for any single radical species. 
 We here describe the hydroxybenzoate (4-hydroxybenzoic 
acid) hydroxylation assay, for the above reasons.
 Fig. 7.  Chromatogram of 4-hydroxybenzoic acid (4-HBA), dihydroxyphenyl acetic acid (DOPAC), and dopamine (DA). 
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  1.  Starting from the day after the surgery, 0.5 mmol/l 
4-hydroxybenzoic acid is added to aCSF solution and perfused 
continuously. 
  2.  Brain dialysates are collected every 20 min, and immediately 
assayed for determination of 3,4-dihydroxybenzoic acid (3,4-
DHBA) (see below Sect.  3.5 ) (Fig.  7 ). 
  3.  After a stable baseline, to induce exogenous hydroxyl radicals 
stimulation, the perfusion  fl uid is switched for 10 min to a  fl uid 
containing 1 mM MPP + or 6-OHDA (or other toxins able to 
induce oxidative stress). 
  4.  Then the perfusion  fl uid is switched back to the previous 
perfusion  fl uid (normal aCSF + 4-HBA), for further 2 h. 
  5.  In control experiments, only aCSF with 4-HBA is used. 
 Dialysate samples are analyzed by reversed-phase HPLC coupled 
with electrochemical detection (Fig.  7 )  ( 13,  14 ) .
  1.  2 L of mobile phase composed of 70 mM NaH 2 PO 4 , 0.1 mM 
Na 2 EDTA, 0.7 mM triethylamine, 0.1 mM octylsulfonic acid, 
and 10% methanol, adjusted to pH 4.8 with orthophosphoric 
acid (see Note 13) are prepared. 
  2.  The mobile phase solution is  fi ltered through 0.22- m m  fi lter 
under vacuum, then degassed by passing a gentle stream of 
ultrapure helium through the solution for 10 min at a pressure 
of 5–10 psi, using Te fl on tubing (see Note 14). 
  3.  Any air bubbles are purged from the mobile phase inlet lines. 
The HPLC/EC system is assembled connecting the mobile 
phase to the inlet lines. The  fl ow rate is setted at 1 ml/min and 
it is allowed several hours (e.g., 14–16 h) for equilibration of 
the mobile phase and column. 
  4.  Cell potential of the  fi rst electrode is adjusted at −175 mV and 
the second at +175 mV, respectively. 
  5.  The electrode sensitivity is adjusted to 500  m A for DOPAC 
and to 5 nA for DA (see Note 15). 
  6.  20  m l of 10–1 nM or less of DA and DOPAC standard working 
solution are injected to determine retention times and stan-
dard curves, used for the linear regression to determine analyte 
concentration (see Note 16). 
  7.  A linear regression analysis of the standards is performed and 
the resulting linear regression equation is used to determine 
actual concentrations in samples. 
 At the end of the experiments, the rats are perfused transcardially 
under deep anesthesia (chloral hydrate) with physiological saline 
(180–200 ml), followed by 4% paraformaldehyde in phosphate 
buffer, pH 7.4 (180–200 ml). 
 3.5.  HPLC Analysis
 3.6.  Immuno-
histochemistry of 
Tyrosine Hydroxylase
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 Brains are removed and cryoprotected by serial passages in 
sucrose in PBS, pH 7.4;  fi rst in 10% sucrose for 24 h and then in 30% 
sucrose for 2–5 days. The brains are then frozen in isopentane −45°C 
and then stored at −80°C. Coronal sections (30  m m thickness) are 
cut using a cryostat microtome, mounted in gelatine-coated slices 
and stained for tyrosine hydroxylase (TH) immunohistochemistry. 
All experiments are done at room temperature. Sections are washed 
and then treated with 0.6% hydrogen peroxide in methanol for 
30 min, washed again, and incubated in a solution containing PBS 
and 50% goat serum for 30 min in a humid chamber. Slices are 
drained and further incubated with policlonal rabbit anti- b TH 
(Abcam Limited Cambridge, UK) 0.15  m g/ m l diluted 1:200 in PBS 
containing 1.5% goat serum and 0.1% Triton-X-100 over night at 
4°C. Sections are then incubated for 2 h with biotinylated goat anti-
rabbit IgG (Vector, 1:200) followed by a second 1-h incubation 
with Avidin Biotinylated horseradish peroxidase macromolecular 
Complex solution (Vectastain ® ABC system, Vector). The peroxi-
dase is then visualized with a standard (Vector) diaminobenzidine/
hydrogen peroxidase chromogen reaction for 5 min. The area which 
shows reduction in TH immunoreactivity around the cannula is 
identi fi ed under a microscope (Fig.  8 )  ( 13 ) . 
 Dopamine and DOPAC content in each sample is expressed as the 
absolute dialysate levels in nmol/l (without considering probe 
recovery). Data correspond to mean ± SEM values of absolute DA 
and DOPAC levels obtained in each experimental group. 3,4-
DHBA content in each sample is expressed as a percentage of the 
average baseline level calculated from three fractions collected 
before neurotoxins infusion. Data are expressed as mean ± SEM of 
the percentage obtained in each experimental group. Data are ana-
lyzed by one-way analysis of variance (ANOVA) with repeated mea-
sures, followed by the Fisher’s protected least signi fi cance difference 
 post hoc test (Fisher’s PLSD) to allow multiple comparisons between 
groups. All statistical analyses are performed with StatView™ ver-
sion 5.0.1 (SAS Institute, Inc., Cary, NC, USA)  ( 13,  14 ) . 
 3.7.  Data Analysis
 Fig. 8.  Photomicrograph of coronal sections (cryostat-cut sections) through striatum (around the microdialysis probe’s 
membrane) after the immunostaining. ( a ) Rat perfused with Ringer’s solution. ( b ) Rat perfused with MPP + . ( c ) Rat perfused 
with 6-OHDA (magni fi cation 32×). Adapted from  ( 13 ). 
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  1.  Stereotaxic surgery requires that the animal be  fi rmly mounted 
into the stereotaxic instrument. No horizontal movement of 
the head should occur. The presence of such indicates improper 
mounting of the animal. Ear bars may require tightening or 
reinsertion. 
  2.  Dilute hydrogen peroxide can be applied to facilitate drying of 
the skull and aid visualization of bregma. This step is critical for 
the proper adherence of dental acrylic to the skull at the end of 
this surgical procedure. 
  3.  A stereotaxic atlas provides coordinates for the anterior–poste-
rior (AP), lateral (L), and dorsal ventral (DV) planes. Accurate 
placement depends on adherence to the reference points used 
for atlas preparation. Depending on the atlas employed, the 
position of the head on the incisor bar may be either above or 
below the interaural line. In addition, brain size may vary 
depending on strain, age, or sex. Pilot studies should be con-
ducted to validate or adjust the coordinates if necessary. 
  4.  The size of the drill bit should be that which will allow lower-
ing of the cannula into the brain without catching the bone. 
Caution should be exercised in drilling so that the meninges 
and underlying brain tissue are not damaged. 
  5.  The screws serve to anchor the cannula/probe assembly when 
dental acrylic is applied. The screws should be rigid but should 
not extend to the dura. 
  6.  For 500 ml aCSF: 2 mM Na 2 HPO 4 (500 ml) and 2 mM 
NaH 2 PO 4 (250 ml) should be prepared. The aCSF salts are 
dissolved in about 350–400 ml of 2 mM Na 2 HPO 4 and 
adjusted to pH 7.4 with 2 mM NaH 2 PO 4 , then bringed to 
500 ml with H 2 O or 2 mM sodium phosphate buffer pH 7.4. 
  7.  Prior to use, any remaining glycerol from dialysis membrane is 
removed by soaking in 70% ethanol for ~5 min. The probe is 
perfused for several minutes with distilled water or perfusion 
 fl uid ( fl ow rate 2  m l/min) and checked for leaks or air bubbles 
inside the membrane. 
  8.  Probe insertion requires a steady hand since it is easy to dam-
age the delicate membrane. Lack of out fl ow, after probe inser-
tion, is often due to occlusion of the out fl ow tubing. This can 
be overcome by cutting the tubing. If this does not result in 
 fl ow, the system (i.e., tubing and pump connectors) should be 
checked for leaks. If  fl ow still does not occur, the probe is 
probably at fault. If such is the case, the probe should be 
removed and inspected for leaks or tears. It is possible to rein-
sert the probe; however, an ample amount of time must then 
elapse before sampling can begin. 
 4.  Notes
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  9.  The out fl ow line must exit the testing cage in such a way that 
the experimenter can remove the collection vial without dis-
turbing the animal. 
  10.  To ensure maximal reproducibility, MPP + or 6-OHDA (10×) 
dissolved in 0.1% ascorbate/saline are prepared in advance, 
 fi ltered through 0.22  m m  fi lters, aliquoted, and stored at −20°C. 
Immediately before use, aliquots gently defrosted, are diluted in 
normal aCSF to the  fi nal concentration of 1 mM each and loaded 
into a designated microdialysis syringe, protected from light. 
  11.  A liquid switch (CMA 110 Liquid Switch) can be used for 
delivery of different perfusates into the region dialyzed. With 
practice, this can also be done manually. Each perfusate switch 
can result in the introduction of air bubbles into the probe 
(resulting in a decrease in the active membrane area). Therefore, 
care must be taken when performing this step. 
  12.  Interestingly, this method can be employed also to study neu-
roregenerative strategies, since Santiago and colleagues  ( 25 ) 
investigated whether a short-lasting infusion of MPP + into the 
SN can be used as a chronic model of parkinsonism, by allow-
ing a 1-month delay after intranigral MPP + administration, and 
it was shown that infusion of MPP + into the SN may cause 
chronic damage to the nigrostriatal pathway. Therefore, using 
various DAergic toxins (e.g., 6-OHDA in SNc) and DA releas-
ing agents such as high K + or amphetamine, besides MPP + , for 
the test challenge of the second day or after 1–2 weeks after the 
lesion, it is possible to employ this method for both the study 
of neuroprotective or restorative treatments for PD. 
  13.  Typically, the mobile phase is recycled and replaced one to two 
times a week. If background noise is detected, however, the 
recycled mobile phase should be degassed once again. Mobile 
phase composition is critical for HPLC/EC detection of dop-
amine and its metabolites. Retention times are affected by 
alterations in room temperature as well as by pH, the concen-
tration of ion-pairing reagent, and the inorganic solvent 
employed. These can be varied to modify analyte resolution. 
Increasing pH decreases the retention time of acidic metabo-
lites (e.g., DOPAC and HVA). Increasing the concentration of 
ion-pairing reagents (e.g., octanesulfonate, octylsulfate, pen-
tanesulfonate, or hexanesulfonate) delays retention of amines, 
enabling better separation from charged molecules. Increasing 
solvent concentration results in a decreased retention time of 
amines and their metabolites. Each of these parameters can be 
modi fi ed to increase analyte resolution. 
  14.  Filtration and complete degassing is essential for sensitive elec-
trochemical detection of catecholamines. Particulate matter in 
the mobile phase can clog the HPLC/EC detector system, 
creating high pressure and baseline disturbances. Air bubbles 
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from improper degassing are the most common problem in 
EC detection and can wreak havoc on an HPLC/EC system. 
  15.  Under these conditions, the sensitivity for DA is about 
0.35 pg/20  m l with a signal to noise ratio of 3:1. 
  16.  Samples are injected manually into the HPLC and detection of 
DA, DOPAC, or 3,4-DHBA is carried out with a coulometric 
detector (Coulochem II, ESA, Bedford, MA, USA) coupled to 
a dual electrode analytic cell (model 5014) (Fig.  7 ). 
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